EANS-Adhoc
Marinomed Biotech AG / Sellers complete accelerated bookbuilding; 105,000 Marinomed shares have been sold for EUR 95 per share
--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------
Capital Measures
22.01.2020
Vienna - 22 January 2020. Acropora Beteiligungs GmbH, VETWIDI Forschungsholding
GmbH and BVT Beteiligungsverwaltung und Treuhand GmbH have completed the offer
of Marinomed shares by means of an accelerated bookbuilding in an amount of in
total 105,000 shares (including a fully exercised upsize option of 50,000
shares); the price was set at EUR 95.00 per share
Marinomed Biotech AG (the "Company") announces that the Company was informed by
the three shareholders Acropora Beteiligungs GmbH ("Acropora"), VETWIDI
Forschungsholding GmbH ("VETWIDI") and BVT Beteiligungsverwaltung und Treuhand
GmbH ("BVT") on 22 January 2020 that Acropora, VETWIDI and BVT have sold in
total 105,000 Marinomed shares from their respective holdings through an
accelerated bookbuilding transaction to institutional investors (the
"Transaction"). Immediately after receiving the notification from Acropora,
VETWIDI and BVT related to the commencement of the Transaction on 22 January
2020, the Company had published this information by means of publication of
inside information and applied for suspension from trading of all Marinomed
shares, ISIN ATMARINOMED6, on the Official Market of the Vienna Stock Exchange.
Due to the publication of the results of the Transaction, trading of the
Marinomed shares on the Official Market of the Vienna Stock Exchange will be
recommenced on the start of the trading day on 23 January 2020.
The following information, put in quotation marks, is taken from the notfication
of the Company by Acropora, VETWIDI and BVT:
"NOT FOR DISTRIBUTION OR PUBLICATION, EITHER DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES OF AMERICA, THE UNITED KINGDOM, CANADA, JAPAN OR AUSTRALIA.
Acropora Beteiligungs GmbH ("Acropora"), VETWIDI Forschungsholding GmbH
("VETWIDI") and BVT Beteiligungsverwaltung und Treuhand GmbH ("BVT") hereby
announce that today, 22 January 2020, Acropora has sold 73,500 Marinomed Biotech
AG shares, ISIN ATMARINOMED6 ("Marinomed shares"), and VETWIDI and BVT have each
sold 15,750 Marinomed shares, thus in aggregate 105,000 Marinomed shares, from
their respective holdings to institutional investors by means of an accelerated
bookbuilding transaction (the "ABB"). This amounts to 7.1 per cent. of Marinomed
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
2 im Artikel enthaltene WerteIm Artikel enthaltene Werte